KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income: 2009-2025

Historic Net Income for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Net Income rose 119.14% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.33%. This contributed to the annual value of $226.5 million for FY2024, which is 469.20% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Net Income stood at $71.8 million for Q3 2025, which was up 169.26% from $26.7 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Net Income peaked at $143.8 million during Q4 2024, and registered a low of -$113.1 million during Q1 2022.
  • In the last 3 years, Acadia Pharmaceuticals' Net Income had a median value of $26.7 million in 2025 and averaged $25.7 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 139.49% in 2023, then skyrocketed by 2,898.20% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Net Income stood at -$43.1 million in 2021, then grew by 3.29% to -$41.7 million in 2022, then skyrocketed by 209.77% to $45.7 million in 2023, then soared by 214.23% to $143.8 million in 2024, then soared by 119.14% to $71.8 million in 2025.
  • Its last three reported values are $71.8 million in Q3 2025, $26.7 million for Q2 2025, and $19.0 million during Q1 2025.